Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Wavelength-Pharmaceuticals-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Zambon Group SpA

              • Development Update

              Virtual BoothCommitted to providing Highly Customized Solutions for all your Development Programs.

              ITALY Italy

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              A new FDA Fast Track designation for Zambon

              Contact the Supplier

              Lead Product(s): Cyclosporin A

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 28, 2020

              Details:

              FDA has granted Fast Track designation to Liposomal Cyclosporine A for Inhalation (L‑CsA‑i), in late-stage clinical development for the treatment of Bronchiolitis Obliterans Syndrome.

              Zambon Group SpA

              • Development Update

              Virtual BoothCommitted to providing Highly Customized Solutions for all your Development Programs.

              ITALY Italy

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              CAMBODIA PHAR-MED 2020

              Participation Not Confirmed

              Update your events

              Breath Therapeutics initiates BOSTON-3 and BOSTON-4 for the treatment of bronchiolitis obliterans syndrome

              Contact the Supplier

              Lead Product(s): Cyclosporin A

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 20, 2020

              Details:

              Liposomal Cyclosporine A for Inhalation (L?CsA?i) is advancing in clinical studies for the treatment for bronchiolitis obliterans syndrome.

              PharmaCompass__DigitalAd